VitalConnect Secures $100M to Expand Real-Time Heart Monitoring Technology

VitalConnect has raised $100 million to accelerate the commercialization of its Vitalpatch, an advanced ambulatory cardiac monitoring device. Unlike traditional Holter monitors, Vitalpatch offers a Band-Aid-like, disposable design that continuously records ECG data and transmits it to the cloud. Competing with iRhythm and Bardy Diagnostics, Vitalpatch sets itself apart by providing real-time monitoring of 21 different cardiac arrhythmias using AI. While it requires more frequent replacement than some competitors’ devices, it also tracks vital signs like respiratory rate and heart rate variability, making it a comprehensive remote monitoring tool.

Since receiving FDA clearance in 2019, VitalConnect has expanded its commercial reach, securing $39 million in 2022 and an additional $30 million in 2023 to scale operations. With sales tripling between 2021 and 2022, the company is now leveraging its latest funding—led by Ally Bridge Group and supported by existing investors—to further develop its technology and collaborate with healthcare providers on inpatient monitoring solutions. This investment positions VitalConnect to compete in the growing market for convenient, real-time cardiac monitoring systems.